3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
105
Neoplasm Metastasis
6
Neoplasms
4
Breast Diseases
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Hereditary Sensory and Autonomic Neuropathies
3
Carcinoma, Ovarian Epithelial
3
Breast Neoplasms, Male
3
Triple Negative Breast Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Endometrial Neoplasms
2
Breast Cancer Metastatic
2
Anatomic Stage II Breast Cancer AJCC v8
2
Advanced Breast Cancer
2
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Osteitis Deformans
1
Neoplastic Cells, Circulating
1
Mesothelioma
1
Lymphoma
1
Lung Neoplasms
1
Locoregional Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Leukemia
1
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
9
Nivolumab
4
budigalimab
2
belinostat
2
Pemetrexed
2
Ipilimumab
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
venetoclax
1
tocilizumab
1
tislelizumab
1
talazoparib
1
spartalizumab
1
rovalpituzumab tesirine
1
ribociclib
1
rebastinib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine
1
epacadostat
1
enzalutamide
1
durvalumab
1
cabozantinib
1
abemaciclib
1
Valacyclovir
1
Sorafenib
1
Sirolimus
1
Quality of Life
1
Plicamycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
ribociclib
×
Breast
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts